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INTRODUCTION 
 
The well known anticoagulant compound heparin was 
discovered in the early 20th century by Howell’s and his student 
L. Emmett Holt Jr. Howell coined the term heparin from the 
Greek ‘hepar’ meaning liver, the tissue utilized in the isolation 
of heparin [1]. The family of glycosaminoglycan (GAGs) 
consists of sulfated and non-sulfated GAGs. The sulfated class 
of GAGs is further subdivided into O-sulfated and N-sulfated 
GAGs. The heparin and long chain less sulfated polymer known 
as heparan sulfate (HS) comes under N-sulfated GAGs 
category. The presence of heparin with its similar structure has 
been noticed in many vertebrate and invertebrate organisms [2] 
including turkey [3], whale [4], camel [5], mouse [6], human 
[7], losbster [8], shrimp [9], mussel [10], species of clam [11] 
and crab [12].  
 
The biochemical characteristic that differentiate HS to 
heparin is basically based on the sulfation pattern, as HS is less 
sulfated than heparin and possesses higher lever of acetylation 
on its glucosamine residue. Heparin is solely produced by the 
mast cells of connective tissues in the form of serglycin, a 
proteoglycan (PG). The complex procedure of biosynthesis of 
heparin in mast cells involves substantial level of sulfation with 
epimerization of its uronic acid. The whole process takes place 
in such a way that more than 80% of the glucosamine can be 
changed into deacetylated form with N-sulfation. The process 
converts 70% of the uronic acid into iduronic acid. HS on the 
other hand exist in association with its PG, the basic structure of 
HS is similar to heparin but bears lower degree of epimerization 
to its iduronate and also with lower level of N- and O- sulfation 
and charge density along the polymer [13]. The major sequence 
of heparin comprises of iduronate residues, often possesses 
sulfation at C2 positions with a N-sulfated glucosamine. Apart 
from sulfation at nitrogen moiety, the amino sugar part 
(glucosamine) is also known to have sulfation at the 6-O 
position. Variation in the pattern of sulfation and its distribution 
provides substantial heterogeneity, which can affect its 
biological properties [14]. The main biological property for 
which heparin is known all over is its ability to act as an anti-
coagulant. The strong anti-coagulant property of heparin is 
mainly because of its ability to potentiate the anti-thrombin 
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Heparin has been in the market since the last six decades due to its potential anticoagulant 
property. The mechanism of its anti-coagulation effect is well established. Along with its 
anticoagulant activity the other activity that is gathering a lot of importance now-a-days is its 
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(AT) based pathway for the inhibition of thrombin and factor 
Xa type coagulation factors.  
 
There are numbers of affinity states between heparin and 
AT with its coagulation factors which ultimately terminates into 
high affinity interactions. There are two possible mechanisms 
by which heparin are known to activate AT. The first is altering 
the structure of AT which allows further interaction between 
heparin and AT results in stronger binding between these two. 
The conformational change also hinders the protease reactive 
centre loop (RCL) in AT. This alteration in structure allows 
interaction of RCL with factor Xa. After complex formation, the 
ATIII bounces back to its original low affinity binding state, 
which results in cleavage of RCL and liberation of heparin from 
the covalent complex of ATIII and factor Xa. The second 
mechanism of heparin anticoagulation activity is known as 
bridging mechanism by which a complete heparin molecule 
facilitate the binding of AT with thrombin. In this mechanism, a 
positively charge thrombin domain binds non-selectively with 
extended polymer of heparin. The length based interaction of 
heparin with serine proteases and AT has already been 
discussed in several studies, despite the fact that only 
pentasaccharide portion of heparin is required to interact with 
AT but a chain of at least 16 monosaccharides are required to 
initiate the interaction of AT with thrombin [15].  
 
Besides of its known anticoagulant activity, heparin 
exhibits several other pharmacological activities due to its 
capacity to interact with diverse proteins. In addition, the 
presence of carboxylate and sulfate group endows it to possess a 
high negative charge (approximately -75), which allows it to 
have electrostatic interaction with many proteins such as growth 
factors, protease and chemokines [16]. Apart from its 
anticoagulant activity, the anti-tumor activity of heparin is 
gaining continuously a substantial ground in upcoming studies, 
due to its inhibitory effect on vascular thromboembolism and on 
the pathway of angiogenesis. Now-a-days researchers are 
focusing on generating short fractions heparin known as low-
molecular-weight heparins (LMWHs) sequence which lack 
anticoagulant property but have more anti-metastatic effect 
allowing the sequence to bind with tumor growth driving 
proteins like P-Selectin and fibroblast growth factors [17]. This 
review will focus on the light molecular weight heparins and 
their anticancer potential.  
 
Light molecular weight heparin as anticancer 
 
Generally, regular fraction of heparin extracted from pork 
intestine or bovine lung lies between the molecular weights of 
5,000 and 40,000 Daltons. Low-molecular-weight heparin is 
depolymerized form of unfractionated heparin comprises of 
heterogeneous sulfated group and are generally used to treat 
venous thromboembolism. The anti-tumor activity is due to its 
potential to inhibit tumor growth, which results improvement in 
survival rate [18]. There are different possible mechanisms 
behind this activity of heparin. One of them is the triggering the 
coagulation cascades or their other components like tissue 
factors which are instinctively involve in tumorigenesis and 
metastasis [19-20]. Several in-vivo studies suggests that’s its 
antimetastatic role is probably due to its anticoagulant effect, 
blocking of heparanase, intervention with P-selectin-HSPG 
interaction and inhibitory effect on tumor adhesion and motility 
[21]. Dargo et al. in their study demonstrated that heparin and 
HS decrease cancer metastasis in the Nb rat prostatic 
adenocarcinoma model [22]. The new low-molecular-weight 
heparin (LMWH) known as revaparin not only block collaged 
adhesion and adenocarcinoma cells invasion of matrigel but 
also decrease their intra-abdominal growth in vivo [23]. Many 
cell-based studies have demonstrated that LMWH can inhibit 
angiogenesis in a dose-dependent manner, while animal studies 
have shown that LMWH can alter tumor progression and 
restrict pulmonary metastasis [24-25]. The phase 2 clinical trial 
of dalteparin another member of LMWH has showed a 
promising effect in reducing ovarian cancer at a dose of 100 
IU/kg [26]. In terms of clinical research, both warfarin and 
heparin have been tried to investigate the influence of 
antithrombotics on cancer. However, more detailed research has 
been conducted on LMWH. The first potential anticancer effect 
of antithrombotics was repoted in 1954 [27]. The first trial of 
ultra-fractionated heparin (ULH) was carried out on 277 
patients, to estimate the action of ULH on the survival of small 
cell lung carcinoma [28]. The patients were randomized to 
receive chemotherapy alone or chemotherapy with dose 
adjusted subcutaneous UFH for 5 weeks. The group treated with 
UFH, attained better median survival of 317 days in comparison 
to 261 days of chemotherapy alone group and also with a better 
survival rate at 1 year (40 vs 30%), 2 year (11vs 9%), and 3 
year (9 vs 6%). The preliminary data to suggesting the effect of 
LMWH in improving the survival of cancer patient is basically 
originated from an evaluation studies comparing UFH with 
LMWH in the first phase of thrombosis treatment [29-30]. 
However, the first study designed to know the effect of LMWH 
on survival rate in cancer was named as Fragmin Advanced 
Malignancy Outcome Study (FAMOUS) study in which 385 
patients with lung, pancreatic, hepatic, advanced breast, 
ovarian, urogenital or uterine cancer were randomized to 
classical chemotherapy with 5000 IU daily dose of dalteparin or 
placebo [31]. The primary end point was mortality at one year. 
The estimate of 1 year survival in the dalteparin and placebo 
cases were 46 and 41%, respectively, for 2nd year the survival 
was 27 and 18% and in the 3rd year it was 21 and 12% for 
dalteparin and placebo group. A post hoc analysis of patients 
who survived more than 17 months indicated a survival benefit 
for dalteparin group.  
 
The perceptible advantage of LMWH with an improved 
prognosis was again shown in another trial having patients with 
metastatic or locally advanced cancer who could not be 
eradicated curatively [32]. In this, 302 patients were 
randomized to receive their regular chemotherapy with a 6-
week regime of weight adjusted nandroparin or placebo. Unlike 
dalteparin, here the primary end point was all-cause mortality. 
At the period of 6 month, the survival estimates were 61% in 
nandroparin group and 56% in placebo. At 12 and 24 months 
the relative estimates were 39 vs 27% and 21 vs 11%. In 
contrast to these studies, another study with a randomized 141 
patients going through the advanced stage of cancer treated with 
LMWH or saline does not produce any significant survival 
advantages with LMWH [33]. This shows that LMWH cannot 
act as anti-tumor alone until incorporated with chemotherapy 
regime. Due to unsatisfactory response, the saline part was 
removed from the study to make it more realistic by comparing 
LMWH with standard care. The median survival reported for 
standard care was 10.5 months in comparison to 7.3 months 
with LMWH. Another study on 84 small cell lung carcinoma 
patients evaluated the efficacy of dalteperin with and without 
chemotherapy [34]. The study reported high overall response 
rate in patients, received LMWH with chemotherapy as the 
survival rate was 69.2% in comparison 42.5% solely by 
chemotherapy. A systematic study and comprehensive analysis 
of all these studies suggests that LMWH with chemotherapy 
produced better survival in cancer patients including those 
patients who are at advance stage of cancer [35-36].  
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Proposed mechanism of action 
 
Inhibition in tumor progression due to anticoagulant 
property 
The exact mechanism of LMWH anti-metastatic role is under 
scrutiny but as per the animal models and cell based research, 
some evidences have came into light which relates its anti-
metastatic activity to its anti-coagulant activity. Clinically, the 
LMWH and un-fractionated heparin has been used from a long 
time as effective blocker of fluid phase coagulation by 
enhancing antithrombin inactivation of factor IIa and Xa. [37-
39]. Another anti-metastatic activity of heparin is mainly by the 
virtue of its anticoagulant effect and is its potential to liberate 
tissue factor pathway inhibitor (TFPI) from vascular 
endothelium. The TFPI is one of the contributors in 
antiangiogenic activity [40-41]. Various studies have 
demonstrated the effect of antimetastatic activity of modified 
heparin with no anticoagulant activity [42-47]. These modified 
heparins ruled out the claim that antimetastatic activity is due to 
anticoagulant effect of heparin. In another study, an excellent 
anticoagulant agent, fondaparinux that mainly potentiate 
antithrombin III, had produced no effect on cancer progression 
at clinically accceptable dose [48-49].  
 
Inhibition of heparinase 
Another important step in the process of cancer progression, 
which drive the invasion of tumor cells is the debasement of 
various building blocks of extracellular matrix, including 
laminin, collagen, fibronectin and HSPGs. Cancer cells usually 
get this job done by employing some hydrolytic enzymes such 
as matrix metaloproteases, serine proteases, cysteine proteases 
and endoglycosidases [50-51]. Among endoglycosidases, 
heparinases secreted by tumor cells can sabotage various 
component favoring tumor invasions. The expression of 
heparinase is very rare in normal tissues but its expression is 
evident in many tumors where it significantly enhances both 
metastasis and angiogenesis [52] of tumors of breast [53], colon 
[54], ovary [55], bladder [56], pancreases [57], acute myeloid 
leukemia [58], non-small cell lung cancer [59] and myelomas 
[60]. Heparinase is a vital enzyme for the cleavage of heparin 
sulfate groups present in heparan sulfate proteoglycans. These 
HS groups possess growth factor having domain associated to 
the protein core with serine residue confined in ECM and in 
plasma membrane of cells. These domains engage growth 
factors, like βFGF and VEGF [61-62] and then act as their co-
factor in cell signaling [63,61]. Heparanase not completely 
cleaves the heparan sulfate chain but it breaks the glycosidic 
bonds at some specific sites, generating sequences, which seems 
even more potent than the parent chain in activation of bound 
growth factors [64-65]. Various study demonstrated that heparin 
and some chemically altered forms of heparin blocked the 
tumor cell heparanase activity [66-70]. Thus, inhibiting 
heparinase can subsequently reduce metastatic potential of 
tumor [71].   
 
Engagement with cell adhesion molecules 
Invasion of tumor cells from one part of body to other part 
usually takes place through intravasation capability of tumor 
cells by which they invade blood vessels and reach to distant 
organs. The intravasation phase is also critical step for tumor 
cells from the prospect of their survival in blood vessels. To 
survive against the immune competent cells present in stream of 
blood, the tumor cells form a complex with platelets [72-73] 
which not only provide a cover that protect them against 
immune system elements but also support their anchoring on 
vascular endothelium [74]. This complex formation between 
tumor cells and platelets is mediated by interaction of 
glycoprotein’s in the plasma membrane of tumor cells to the 
selectins of platelets and endothelium. 
 
Transformed glycosylation of cell-surfaced mucins is a 
leading feature of tumor growth. Some of these transformations 
are related with carcinomas (Cancer originate from epithelial 
cells). Sialyl Lewisx and Lewis a are two of such epitopes found 
on the carcinoma mucins that are usually associated with tumor 
progression. Selectins act as adhesion receptors that recognize 
these altered glycosylated structures. Their physiological role in 
facilitating cell adhesion has already been demonstrated in 
inflammations, immune responses and wound repairs [75-76]. 
Selectins are basically  adhesion molecules responsible for 
initiating the first step for cell adhesions and in the absence of 
selectins, all the steps are initiated by secondary elements of 
adhesion process such as integrins and other adhesion 
molecules are eventually delayed or do not occur. Selectins are 
expressed by leukocytes (L-selectin), platelets (P-selectin), and 
the vascular endothelium (E and P selectin). However, L 
selectin mainly exist on neutrophils, monocytes, and naïve 
lymphocytes. The secretory granules of resting platelets and 
endothelium stores P-selectins, which is rapidly shifted on cell 
surface and the process is triggered by histamine and thrombin. 
E-selectin is entirely produced by endothelial cells on getting 
activated by various inflammatory factors such as TNF-alfa, IL-
I and endotoxins [77].  All these three selectins can interact with 
sialyted, fucosylated or with sulfated glycans on proteoglycans, 
glycoproteins and glycolipids. The tetrasaccharide epitope 
Sialyl Lewisx and Lewisa have been found as a minimum ligands 
for binding with all three types of selectin. The validation of 
selectins as a target for anti-cancer therapy has been already 
realized in animal based models. A substantial decline in 
platelet-tumor cell thrombi formation has resulted in 
diminishing of metastasis has been reported in P-selectin 
deficient mice [78]. Role of E-selectin in metastasis has also 
been validated in transgenic mice with overexpression of E-
selectin, which resulted in increase in liver metastasis [79]. 
Reduction in metastasis is also observed in two L-selectin 
knocked out mice models, thus actively suggesting the role of 
leukocytes in aggravating metastasis [80].  
 
Heparin has the potential to inhibit selectins even with no 
similarity to selectin ligands [81]. The anti-coagulation effect of 
heparin increase time of cancer cells to be in blood vessels by 
limiting their adhesion to endothelium and platelets. This makes 
the tumor cells more vulnerable to get neutralized by NK cells 
in circulation [82]. Several laboratories have analyzed the effect 
of heparin on selectins. In one such experiment, the UFH is 
injected in P and L selectin-knocked out mice shortly after the 
injection of melanoma cells. [83-84]. Single bolus injections of 
heparin have been identified to reduce metastasis in wild type 
mice in a similar way as in P-selectin deficient mice [83]. In 
addition to this, a single heparin injection in P-selectin knocked 
out mice produces no marked change on metastasis [74]. 
Interestingly, a single dose of heparin injected in L-selectin 
deficient mice just before to tumor cell injection resulted in 
further reduction in metastasis [80]. When heparin is injected 
shortly before or six hours after tumor cell injection, no further 
attenuation on metastasis in P- and L-selectin is observed. 
However, repeated injection of UFH causes increase in survival 
of mice, suggesting that heparin at such doses might have 
further antimetastatic activities apart from selectin blocker. A 
detailed characterization of non-anticoagulant heparin resulted 
in identification of specific heparin analogue (58% N-acetylated 
heparins), that holds outstanding P-selectin inhibition property 
while holding minimal heparinase activity and also with 
reduced growth factor interaction ability [85]. This heparin 
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analogue is found to reduce metastasis colon carcinomas and 
melanomas cells. Overall, these results strongly indicate that 
heparin block metastasis by interfering with selectin based cell-
cell adhesion.   
 
Blocking of cell surface proteoglycans 
Another mechanism of heparin antimetastatic action may lies in 
its ability to compete with the HS group present on the Heparan 
sulfate proteoglycans (HSPGs) to bind with growth factors and 
may liberate these proteins from ECM [86]. Studies on human 
in vitro angiogenesis model proves that both UFH and LMWH 
are capable of inhibiting βFGF- induced angiogenesis by 
blocking the interaction βFGF with HS. In man, therapeutic 
dose of UFH can indeed cause a hike in plasma levels of growth 
factors, such as βFGF [87-89]. Contradictory to this, Soker et 
al. demonstrate that LMWH but not UFH can block the 
interaction of growth factor to their high affinity receptors due 
to its smaller size [90-91]. Heparin fragment of less than 18 
saccharide units has been identified to reduce the activity of 
VEGF [92] and fragment of less than 10 saccharide units can 
inhibit the activity of βFGF [93-94]. In one more such 
contradiction to UFH, the LMWH has also been demonstrated 
for inhibiting βFGF and VEGF-facilitated angiogenesis in vivo 
[95]. The true relevance of HSPGs and growth factor as a 
potential target for heparin is very perplexed and unpredictable.  
 
Heparin based nanoparticle and other innovative 
pharmaceutical approach to target tumors 
 
The major issue today’s modern chemotherapy is facing is harsh 
side effects of cytotoxic drugs due to their lack of specificity 
which can only be resolved by targeted drug delivery [94]. To 
overcome drug delivery issue, pharmaceutical modification in 
dosage form by making polymer drug conjugates are one of the 
approach that has been employed in past few years [90]. The 
approach has been shown to offer advantages in targeting tumor 
through a passive way by increasing the permeability and 
retention factor, which ultimately lead to reduction in noxious 
effect and increase in solubility as well as chemical stability. 
The advantage of polymer drug conjugates has been observed in 
a phase I trial where increase efficacy has been reported in 
forty-three patient with advanced solid tumor treated with 
cisplatin and poly (L-glutamic acid)-paclitaxel conjugate (PGA-
PTX). Nevertheless, the challenges to find polymer with 
suitable physiochemical and biopharmaceutical properties are 
major hurdle in developing a selectively targeted polymer- drug 
conjugated therapy [95]. To deal with this issue, heparin, which 
is a biodegradable, non-cytotoxic, and water-soluble natural 
polysaccharide coupled with variety of paharmacological 
activities such anti-coagulation, anti-inflamation, anti-
angiogenesis and anti-tumor [96], has allured intense attention. 
Taking advantage of this unique property of heparin, many 
heparin-drug conjugates have been developed for cancer 
chemotherapy [97]. In one such attempt, a LMWH based 
polymer drug conjugate holding two different anti-tumor drugs, 
Paclitaxel and all-trans-retinoic acid (ATRA) has been 
synthesized by Hou et al. The conjugate was reported to have 
less toxicity with better antitumor activity due to better 
permeability of nano-particles which increased the influx of 
paclitaxel (PTX) bound conjugate in tumor cells. The ATRA, 
which is known to induce regression of tumor by down 
regulating the survival factors of tumor and by activating of 
mitochondria dependent apoptosis, has played a significant role 
in the facilitating the transport of paclitaxel in the nucleus of 
tumor cell [98]. Beside heparin based nano-particles 
development, other approaches such as development of heparin 
based microcapsules loaded with anti-cancer drugs like 
doxorobucin has also take pace in past few years. In one such 
study doxorobucin has been encapsulated with layer-by-layer 
assembly of heparin and chitosan. Use of chitosan is mainly to 
prevent degradation of heparin from heparanase and also to 
facilitate the cellular uptake of heparin as the heparin is 
negatively charge that prevents it to move across the cell 
membrane, layer of positively charge chitosan applied to 
counter this effect. Thus, a synergistic response has been 
obtained against A549 cell lines [99]. Beside conjugation of two 
active anti-tumor agents, the attempt to make heparin-based 
nanoparticles also employed conjugation of florescent dye 
labeled heparin with gold nanoparticles.  
 
Gold nanoparticles are widely used in many studies for 
their role in detection of biomolecules [100], selective marking 
of cells and proteins [101], killing tumor cells by hyper-thermal 
treatment and delivering therapeutic agent inside cells. In a 
study by Lee et al., heparin immobilized gold nanoparticles 
were prepared to optically identify the metastatic stage of tumor 
cells as well as to initiate apoptosis-induced tumor death by 
loading heparin into the cells. The nanoparticles were prepared 
by sealing the florescent heparin at the surface of gold nano-
particles via gold-thiol interaction to obtain florescence 
resonance energy transfer (FRET). These nanoparticles were 
further conjugated with arginine-glycine-aspartic acid, a cell 
adhesive peptide to make it more effective for inducing 
apoptosis. The study achieved acute apoptosis in αvβ3 integrin 
expressing cancer cells due to targeted influx of heparin in 
cytoplasm of cancer cells [102]. In addition to all this 
innovations, Alam et al. recently conjugated a potent anti-
angiogenic analogue of heparin (LHT7) with tetrameric 
deoxycholic acid to prepare an oral formulation of heparin with 
better bioavailability [103]. The LHT7 has also been studied for 
its conjugation with reduced graphene oxide nanoparticles in a 
separate study. In this, light molecular weight heparin analogue 
coated with nano sheet of reduced graphene oxide is further 
loaded with doxorubin. The particles are found to have a better 
dispersion in tumor vasculature of KB carcinoma bearing mice 
with better efficacy possibly due to synergistic effect of 
doxorubicin and LHT7 [104].  
 
Conclusion 
Heparin is the most negatively charged and important member 
of the GAG family and is commercially available in the market 
as a potential anticoagulant. Presence of heparin in various 
species has already been well documented but major 
commercial sources are still limited to porcine intestine and 
bovine lungs. Biological properties of heparin have been found 
to largely depend on its sulfation pattern. The properties also 
differ on the basis of its distribution in various vertebrates and 
invertebrates. The anticoagulant features of heparin have 
already been well studied and documented in various studies. 
The mechanism of anticoagulant activity of heparin is well 
established and known. Beside from its anticoagulant role, 
heparin has been explored in the past few decades for its anti-
tumor properties, a role which gained much momentum after 
the development of some light molecular weight fractions of 
heparins (LMWH) along with unfractionated heparin (UFH) 
and non sulfated heparins with little or almost no anticoagulant 
properties. The process of tumor growth has been known to be 
highly complicated as many hallmarks of cancer such as 
angiogenesis and metastasis use different tactics to make the 
progression simplified for tumor cells. There is enough 
evidence suggesting heparin as a potential therapeutic agent 
against cancer. Various experimental studies have already 
demonstrated the efficacy of heparin in arresting tumor growth 
both in vitro and in vivo models. Clinical trials of some of the 
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LMWH have already shown better survival rate and regression 
of solid tumors especially in lung carcinoma patients. The 
clarity on its actual mechanism of action is still not clear. As 
some studies suggest that it interfere the progression of tumor 
by its anticoagulant property while other point out its interaction 
potential to engage cell adhesion molecules and proteoglycans. 
A synergistic and selective approach of heparin-based 
nanoparticles loaded with classical anti-cancer drugs such as 
paclitaxel and doxorubicin to target tumor cells, has been 
obtained by several studies. It can be concluded that heparin 
have a potential to serve itself as an anticancer agent or can 
complement the treatment in combination with other anti-cancer 
agent to minimize the harsh side effects and chemotherapy. 
Apart from the need to give much emphasis on a clear cut 
mechanism of mechanism of its action there are some other 
issue which are also needed to be addressed such as: what type 
of heparin, what dose is needed, what duration of administration 
are optimum for better anticancer outcome. These questions 
urgently needed to be answered so that design of prospective 
randomized clinical trial especially in patients with early 
metastasis can take place.  
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